This is a community marketing and branding partnership with no disclosed financial commitment. Monitor for any future revenue or cost guidance related to the partnership, but no immediate financial impact is expected.
Price Chart
Executive Summary
Collegium Pharmaceutical announced an expanded multi-year partnership with Boston Legacy FC, a professional women's soccer club, to support neurodivergent children and families, including those with ADHD. The partnership includes a coaching certification initiative, an annual summit, continued sensory room support, and increased branding on team kits. No financial terms were disclosed.
Key Facts
- Expanded multi-year partnership with Boston Legacy FC, building on existing Collegium Sensory Room partnership.
- New programs include a coaching certification initiative (planned launch in Massachusetts in 2027), an annual Collegium Summit: Sports for All, and continued sensory inclusion.
- Collegium's logo will appear on the upper back of all Boston Legacy FC game kits (primary, secondary, goalkeeper) at every home and away match.
- Permanent signage on the press box at White Stadium.
- No financial terms or deal value disclosed.
- Partnership extends Collegium's local commitment ahead of its headquarters move to Boston in early 2027.
Financial Impact
No financial terms disclosed; likely immaterial relative to Collegium's $749M market cap.
Risk Factors
- No financial terms disclosed, making it impossible to assess materiality.
- Partnership may not translate into measurable revenue or earnings impact.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3391167 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 30, 2026 2d ago | SC 13G/A | $24.23 | awaiting T+1 | awaiting T+1 | $23.80 (−1.77%) |
Oct 29, 2026 3d ago | SC 13G/A | $24.03 $23.80 | ▼ −0.96% | ▲ +0.82% | $23.80 (−0.96%) |
Oct 29, 2026 3d ago | Press Release | $24.03 $23.80 | ▼ −0.96% | ▲ +0.82% | $23.80 (−0.96%) |
Oct 22, 2026 10d ago | Press Release | $23.50 $22.96 | ▼ −2.30% | ▼ −1.78% | $23.80 (+1.28%) |
Oct 19, 2026 13d ago | 8-K | $23.23 $22.92 | ▼ −1.36% | ▼ −1.88% | $23.80 (+2.45%) |
Oct 8, 2026 24d ago | SC 13G/A | $22.09 $22.05 | ▼ −0.18% | ▼ −0.12% | $23.80 (+7.74%) |
Aug 19, 2026 10w ago | Court Ruling | $27.54 $27.11 | ▼ −1.56% | ▼ −1.97% | $23.80 (−13.58%) |
Aug 13, 2026 11w ago | 8-K | $28.15 $28.23 | ▲ +0.28% | ▲ +0.48% | $23.80 (−15.45%) |
Aug 6, 2026 12w ago | 8-K | $29.11 $29.47 | ▲ +1.24% | ▲ +0.63% | $23.80 (−18.24%) |
May 15, 2026 24w ago | Insider Cluster | $33.65 $33.62 | ▼ −0.09% | ▲ +0.56% | $23.80 (−29.27%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers